Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited
Why it matters: Investors should weigh AbbVie's current success and diversification efforts against potential growth limitations and consider alternative investment opportunities in sectors like AI.
- AbbVie (ABBV) reported strong full-year results, exceeding initial revenue expectations by over $2 billion and forecasting a 9.5% revenue increase in 2026 driven by Skyrizi and Rinvoq.
- Evercore ISI lowered its price target on ABBV from $232 to $228, maintaining an Outperform rating but cautioning that buy-side projections may limit future earnings gains, especially post-2028 as rival treatments emerge.
- AbbVie is expanding its pipeline into psychedelic-inspired mental health treatments, signaling a strategic shift beyond traditional therapies, while other analysts suggest that AI stocks offer greater upside potential.
Despite AbbVie's Tremfya gaining market share and exceeding revenue expectations, Evercore ISI suggests future earnings growth may be limited due to buy-side projections outpacing consensus and investor concerns about post-2028 growth. AbbVie is strategically diversifying into psychedelic-inspired mental health treatments, but some analysts believe AI stocks offer greater upside potential.
